- Home
- AEYE vs ACRS Comparison
AEYE vs ACRS Comparison
Compare AEYE & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEYE
- ACRS
- Stock Information
- Founded
- AEYE 2005
- ACRS 2012
- Country
- AEYE United States
- ACRS United States
- Employees
- AEYE 117
- ACRS N/A
- Industry
- AEYE Computer Software: Prepackaged Software
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- AEYE Technology
- ACRS Health Care
- Exchange
- AEYE Nasdaq
- ACRS Nasdaq
- Market Cap
- AEYE 138.0M
- ACRS 127.6M
- IPO Year
- AEYE N/A
- ACRS 2015
- Fundamental
- Price
- AEYE $11.92
- ACRS $1.30
- Analyst Decision
- AEYE Strong Buy
- ACRS Strong Buy
- Analyst Count
- AEYE 5
- ACRS 7
- Target Price
- AEYE $26.40
- ACRS $11.67
- AVG Volume (30 Days)
- AEYE 117.3K
- ACRS 832.4K
- Earning Date
- AEYE 04-29-2025
- ACRS 05-08-2025
- Dividend Yield
- AEYE N/A
- ACRS N/A
- EPS Growth
- AEYE N/A
- ACRS N/A
- EPS
- AEYE N/A
- ACRS N/A
- Revenue
- AEYE $36,851,000.00
- ACRS $17,777,000.00
- Revenue This Year
- AEYE $20.29
- ACRS N/A
- Revenue Next Year
- AEYE $18.65
- ACRS $425.96
- P/E Ratio
- AEYE N/A
- ACRS N/A
- Revenue Growth
- AEYE 16.52
- ACRS N/A
- 52 Week Low
- AEYE $8.91
- ACRS $0.95
- 52 Week High
- AEYE $34.85
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- AEYE 52.10
- ACRS 43.35
- Support Level
- AEYE $11.17
- ACRS $1.20
- Resistance Level
- AEYE $12.44
- ACRS $1.31
- Average True Range (ATR)
- AEYE 1.03
- ACRS 0.10
- MACD
- AEYE 0.09
- ACRS 0.02
- Stochastic Oscillator
- AEYE 74.46
- ACRS 43.04
About AEYE AudioEye Inc.
AudioEye Inc is a software solution provider delivering immediate ADA and WCAG accessibility compliance at scale. Through patented technology, subject matter expertise and proprietary processes, it is eradicating all barriers to digital accessibility, helping creators get accessible and supporting them with ongoing advisory and automated upkeep. Trusted by the ADP, Tommy Hilfiger, A360 Media, Samsung, Landry's and others. It helps everyone identify and resolve issues of accessibility and enhance user experiences, automating digital accessibility for the widest audiences.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.